PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Trial Profile

PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2018

At a glance

  • Drugs CP 101 Crestovo (Primary)
  • Indications Clostridium-difficile-infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRISM-EXT
  • Sponsors Finch Research & Development
  • Most Recent Events

    • 02 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 17 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top